IRAK inhibitor 1 NEW
Price | $87 | $127 | $213 |
Package | 1mg | 2mg | 5mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-15 |
Product Details
Product Name: IRAK inhibitor 1 | CAS No.: 1042224-63-4 |
Purity: 97.78% | Supply Ability: 10g |
Release date: 2024/11/15 |
Product Introduction
Bioactivity
名稱 | IRAK inhibitor 1 |
描述 | IRAK inhibitor 1 is an effective IRAK-4 inhibitor (IC50: 216 nM), is poorly active against JNK-1 (IC50: 3.801 μM) and JNK-2 (IC50>10 μM). |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 10 mg/mL (34.09 mM), Sonication is recommended. |
關(guān)鍵字 | Inhibitor | inhibit | Interleukin-1 receptor associated kinase | IRAK inhibitor 1 | IL-1R associated kinase | IRAK inhibitor1 | IRAK inhibitor-1 | IRAK |
相關(guān)產(chǎn)品 | Astragaloside IV | ANTHRAQUINONE-2-CARBOXYLIC ACID | Anisomycin |
相關(guān)庫 | 神經(jīng)退行性疾病化合物庫 | 經(jīng)典已知活性庫 | 疼痛相關(guān)化合物庫 | 激酶抑制劑庫 | 抑制劑庫 | 抗衰老化合物庫 | 已知活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$2500.00/100mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
$0.01/1KG |
VIP5Y
|
Career Henan Chemica Co
|
2020-10-27 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY